Cancer genetics & biology lab, building and applying new genetic technologies in search of better treatment options for cancer patients
Manhattan, NY
Joined March 2018
- Tweets1.8K
- Following725
- Followers2.9K
- Likes2.4K
Pinned Tweet
Paper day! This one is a fantastic joint effort from @alynakatti and @AdrianVegaPerez. I tweeted about this >1 year ago when the #preprint dropped, but there was a lot added in review, so... here is iBE - a new inducible #baseediting mouse model! 1/15 go.nature.com/3KzCo2i
Dow Lab retweeted
We now have our confirmed speaker list, bringing you plenty of opportunities to learn, connect and discuss the latest insights.
At #3MC we will discuss how modeling cancer drives our fundamental understanding of the disease and how discoveries can be leveraged to chart new frontiers in medicine.
Talk titles emerging - Click here to receive further conference updates: bit.ly/4ifFtGr
Dow Lab retweeted
Confirmed speaker list for the #3MC conference is now live!
Join leading experts at the conference to network, share your research, and gain valuable feedback.
Click here to sign up for updates: bit.ly/4fAS8AV
Dow Lab retweeted
📢SAVE THE DATE!
3rd Modeling Cancer Conference: Discovery, Mechanisms & Translation
📅Date: 19 - 22 May 2027
🌏Location: Durrës, Albania
Sign up for updates to find out more information on the conference: bit.ly/4xCLDFV
#FusionCancerResearch
Dow Lab retweeted
New work from the lab of Dr. Lukas Dow (@dow_lab) at @WCM_MeyerCancer shows that #ColorectalCancers develop resistance to KRAS-targeted therapy through a mix of genetic mutations and adaptive inflammatory cell states.
📖 Read the @Cancer_Cell study: bit.ly/4uiYGJW
Dow Lab retweeted
Our paper, co-led with @kevanchu in the @dow_lab, is out today in @Cancer_Cell. We analyzed pre-treatment, on-treatment, and post-progression biopsies from 12 CRC patients treated with KRASi + EGFRi.
authors.elsevier.com/c/1n8Il…
Dow Lab retweeted
Preprint from @dow_lab @WeillCornell using CRISPR base editing screens:
Genetic mechanisms of resistance to targeted KRAS inhibition
biorxiv.org/content/10.1101/…
MAPK reactivation remains the predominant mechanism of resistance to KRASinh. Also identifies a hotspot mutation in CiC.
Dow Lab retweeted
Excited to share the preprint of my postdoc work @dow_lab and @MSKCancerCenter! Joint work with co–first author @kevanchu
Link: doi.org/10.1101/2025.08.05.6…
Haven't been on here since the first Tuesday in Nov, but...
...today I was promoted to Professor with tenure at @WeillCornell and wanted to post one last time to thank everyone that has helped our lab over the past 10 years! Science and guitar posts continue @dowlab.bsky.social
Alright, America… Let’s see if we can (finally) elect a more than qualified female candidate over an abundantly unqualified male. I’m looking at you, PA & WI. Vote!!
Ok, so unpopular opinion, I guess… I don’t think news entities should ever endorse political candidates.
They can and SHOULD report objectively on all the terrifying stuff coming from DJT. I’d much rather honest reporting than ‘both-sidesing’ and editorial opinions. Inform us!
Dow Lab retweeted
6 years of work +
Over 2 years in review +
1 extremely talented graduate student @LeonaNease +
Amazing collaborators =
One extremely cool new mechanism that regulates metastasis through modification of the selenocysteine tRNA!
nature.com/articles/s43018-0…
In no other field do you hire someone for their immense expertise in a very niche field and immediately ask them to change what they do… science is weird.
Dow Lab retweeted
Distinct clinical outcomes & biological features of
specific KRAS mutants in human pancreatic cancer
@Cancer_Cell
doi.org/10.1016/j.ccell.2024…
👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence
👉improved OS
🧐 Supports KRAS mutational testing in #PDAC
@myesmo
Dow Lab retweeted
@dow_lab we're looking forward to your presentation at #AMC25 in the Dominican Republic🇩🇴 next February! Please RT to let your followers know Talk Submission closes next week!
✅Register & Submit: bit.ly/3BbtGoY
Dow Lab retweeted
Online Now: Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer dlvr.it/TCXth0
Sharing this for twitterless (X-less?) Rohit Chandwani - a great clinical dive into differences between KRAS G12D/V and G12R mutations. Mirrors clear differences we see in mice. Happy we could contribute a small part to this work. G12R is an odd duck... sciencedirect.com/science/ar…
